trial

A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia

NCTId NCT00222794
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 66
Sponsored by University of Pittsburgh Medical Center
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
66
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2003-11
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Atomoxetine (Strattera)

Sponsors

University of Pittsburgh Medical CenterLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Rohan Ganguli, MDPrincipal Investigator

Sites

1 total
Pittsburgh, United States

Facts & assertions

3 sourced
Enrollment
66
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Atomoxetine (Strattera)
drug
lead_sponsor
University of Pittsburgh Medical Center
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Rohan Ganguli, MD
person